New insights into the treatment of pulmonary fibrosis

被引:0
作者
Yurovsky, VV [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
alveolitis; bleomycin; collagen; extracellular niatrix; fibroblast; interstitial lung disease; pulmonary fibrosis; sclerodema; silicosis;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Pulmonary fibrosis is a serious outcome of chronic lung inflammation or environmental exposure. it is characterised by the replacement of lung epithelial tissues by fibroblasts in the repair process following lung injury and by excessive deposition of extracellular matrix that ultimately leads to a loss of functional gas exchange units. Current therapeutic strategies are aimed predominantly at suppressing lung inflammation, the role of which has been documented in the development of fibrosis. Data generated over recent years indicate that fibroproliferation and abnormalities in epithelial repair may have a greater pathophysiological role than inflammation, thus representing new opportunities for therapeutic interventions. This review examines the patent literature in this area from 1999 to 2002 with some discussion of primary literature and older citations when appropriate.
引用
收藏
页码:957 / 967
页数:11
相关论文
共 107 条
[1]   FAS ANTIGEN SIGNALS PROLIFERATION OF NORMAL HUMAN-DIPLOID FIBROBLAST AND ITS MECHANISM IS DIFFERENT FROM TUMOR-NECROSIS-FACTOR RECEPTOR [J].
AGGARWAL, BB ;
SINGH, S ;
LAPUSHIN, R ;
TOTPAL, K .
FEBS LETTERS, 1995, 364 (01) :5-8
[2]  
AGGARWAL BB, 1991, CYTOKINE REFERNECE, P413
[3]  
AJINOMOTO CO LTD, 2000, Patent No. 1004302
[4]  
ALTEON INC, 2002, Patent No. 0207725
[5]  
ASTRAZENECA, 2000, Patent No. 0046196
[6]  
AVENTIS PHARM PRODUC, 2001, Patent No. 0190101
[7]  
Barker A.J., 1999, International Patent Application Publication, Patent No. [9907351 A2, 9907351]
[8]  
BIOGEN INC, 2000, Patent No. 00664474
[9]  
BIOMEDICINES INC, 2002, Patent No. 0236072
[10]  
BOSTON U, 2002, Patent No. 0202123